Opinion|Videos|August 26, 2024
Advancements in MIST for BPH: Options, Guidelines, and Patient-Centered Decision-Making
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, covers minimally invasive surgical therapies (MIST) for BPH, including laser therapy, prostatic urethral lift, and others, their impact on BPH management, AUA guidelines, patient selection, and the role of patient preference in choosing between MIST, medication, and surgery.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you please provide a high-level overview of the following available minimally invasive surgical therapies (MIST) options for benign prostate dysplasia (BPH) and how they work?
- Laser therapy
- Prostatic urethral lift procedure
- Water vapor thermal therapy
- Robotic waterjet treatment
- Photoselective vaporization of the prostate
- Any other novel therapeutic options
- How has the emergence of MIST impacted the management of patients with BPH?
- What are the current American
- Which patients make good candidates for MIST options?
- When/why do you consider a MIST vs surgery (patient prognosis, patient preference, comorbidities)?
- What role does patient preference play in choosing medication vs surgery vs a MIST? Please speak to the importance of shared decision-making.
Advertisement
Related to this article
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
4
ENVISION data inform the use of chemoablation in recurrent LG-IR-NMIBC
5